

likhiun

CONTROVER
UNRESOLVE



ND
ES

lithium

CONTROVERSIES AND UNRESOLVED ISSUES

Proceedings of the International Lithium Conference,
New York, June 5-9, 1978

Sponsored by
National Institute of Mental Health
New York University School of Medicine
Rockland Research Institute

Editors

T. B. Cooper
S. Gershon
N. S. Kline
M. Schou



1979

Excerpta Medica, Amsterdam-Oxford-Princeton

© Excerpta Medica 1979

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without permission in writing from the publisher.

International Congress Series No. 478

ISBN Excerpta Medica 90 219 0408 X

ISBN Elsevier North-Holland 0 444 90093 4

Publisher:

Excerpta Medica
305 Keizersgracht
1000 BC Amsterdam
P.O. Box 1126

Sole Distributors for the USA and Canada:

Elsevier North-Holland Inc.
52 Vanderbilt Avenue
New York, N.Y. 10017

ORGANIZING COMMITTEE

Samuel Gershon, M.D.
Professor of Psychiatry
New York University
School of Medicine

Nathan S. Kline, M.D.
Director
Rockland Research Institute

Mogens Schou, M.D.
Professor of Psychiatry
Aarhus University

PROGRAM CONSULTANT

Heinz E. Lehmann, M.D.
Professor of Psychiatry
McGill University

SECRETARY OF THE CONFERENCE

Thomas B. Cooper, M.A.
Rockland Research Institute

CONFERENCE CHAIRMEN

SAMUEL GERSHON, M.D.
NATHAN S. KLINE, M.D.
MOGENS SCHOU, M.D.

GUEST OF HONOR

JOHN CADE, M.D.
Toorac, Victoria
Australia

GUEST SPEAKER

FRANK M. OCHBERG, M.D.
Acting Director
Office of Program Development
and Analysis
National Institute of
Mental Health
Bethesda, Maryland

DELEGATES

Amdi Amdisen, M.D.
Assistant Research Director
Psychopharmacology
Research Unit
Aarhus University
Risskov, Denmark

Poul Chri Baastrup, M.D.
Clinical Director
Statshospitalet
Glostrup, Denmark

Per Bech, M.D.
Psychochemistry Institute
University of Copenhagen
School of Medicine
Copenhagen, Denmark

N. J. Birch, Ph.D.
Department of Biochemistry
University of Leeds
Leeds, England

Monte Buchsbaum, M.D.
Chief, Unit on Perceptual
& Cognitive Studies
Biological Psychiatry
Branch
National Institute
of Mental Health
Bethesda, Maryland

William E. Bunney, Jr., M.D.
Chief, Biological
Psychiatry Branch
National Institute
of Mental Health
Bethesda, Maryland

**Bernard J. Carroll, M.D.,
Ph.D.**
Professor of Psychiatry
University of Michigan
Medical School
Ann Arbor, Michigan

Thomas B. Cooper, M.A.
Rockland Research Institute
Orangeburg, New York

A. Coppen, M.D.
Neuropsychiatry Laboratory
West Park Hospital MRC
Epsom, Surrey, England

John M. Davis, M.D.
Director of Research
Illinois State
Psychiatric Institute
Chicago, Illinois

David L. Dunner, M.D.
New York State
Psychiatric Institute
New York, New York

Richard B. Ebstein, Ph.D.
Senior Scientist
Jerusalem Mental Health Centre
Jerusalem, Israel

Barbara E. Ehrlich, Sc.B.
Department of Physiology
University of California -
Los Angeles
Center for Health Sciences
Los Angeles, California

Ronald R. Fieve, M.D.
Director, Lithium Foundation
for Depression and
Manic Depression
New York, New York

John N. Forrest, Jr., M.D.
Associate Professor of
Medicine
Yale University
School of Medicine
New Haven, Connecticut

Alan Frazer, Ph.D.
Veterans' Administration
Hospital
Philadelphia, Pennsylvania

Elliot S. Gershon, M.D.
Chief, Section
on Psychogenetics
Biological Psychiatry Branch
National Institute
of Mental Health
Bethesda, Maryland

Samuel Gershon, M.D.
Professor of Psychiatry
New York University
School of Medicine
New York, New York

J. C. Gillin, M.D.
Deputy Chief,
Laboratory of
Clinical Psychopharmacology
National Institute
of Mental Health
Bethesda, Maryland

A. I. M. Glen, M.D.
MRC Brain Metabolism Unit
Thomas Clouston Clinic
University of Edinburgh
Edinburgh, Scotland

F. K. Goodwin, M.D.
Chief, Clinical
Psychobiology Branch
National Institute
of Mental Health
Bethesda, Maryland

Waldemar Greil, M.D.
Psychiatric Clinic
University of Munich
Munich, West Germany

**Paul Grof, M.D., Ph.D.,
F.R.C.P. (C)**
Professor of Psychiatry
McMaster University
Hamilton, Ontario, Canada

G. Heninger, M.D.
Yale University
School of Medicine
New Haven, Connecticut

**D. F. Horrobin, M.A.,
D. Phil., B.M., C.Ch.**
Director, Endocrine
Pathophysiology Laboratory
Clinical Research Institute
Montreal, Quebec, Canada

R. P. Hullin, Ph.D.
Regional Metabolic Research
Unit
High Royds Hospital
Yorkshire, England

James W. Jefferson, M.D.
Director, Lithium Information
Center
University of Wisconsin
Center for Health Sciences
Madison, Wisconsin

F. A. Jenner, M.D.
MRC Unit for Metabolic Studies
in Psychiatry
Middlewood Hospital
Sheffield, England

F. N. Johnson, Ph.D.
Senior Lecturer
Department of Psychology
University of Lancaster
Lancaster, England

Alan Judd, Ph.D.
School of Pharmacy
Sunderland Polytechnic
Sunderland, England

Lewis L. Judd, M.D.
Professor of Psychiatry
University of California -
San Diego
La Jolla, California

Nathan S. Kline, M.D.
Director
Rockland Research Institute
Orangeburg, New York

Heinz E. Lehmann, M.D.
Professor of Psychiatry
McGill University
Montreal, Quebec, Canada

Bonaventure Lena, M.D.
Consultant in Child and
Adolescent Psychiatry
District General Hospital
Eastbourne, E. Sussex, England

Arnold J. Mandell, M.D.
Professor of Psychiatry
University of California –
San Diego
La Jolla, California

J. Mendels, M.D.
Professor of Psychiatry
University of Pennsylvania
School of Medicine
Philadelphia, Pennsylvania

**Julien Mendlewicz, M.D.,
Ph.D.**
Senior Psychiatrist
U.L.B. Hôpital ERASME
Brussels, Belgium

Julius Merry, M.D.
Department of Psychiatry
Epsom District Hospital
Epsom, Surrey, England

**B. Müller-Oerlinghausen,
M.D.**
Professor of Clinical
Psychopharmacology
Psychiatric Department
Free University of Berlin
Berlin, West Germany

Dennis L. Murphy, M.D.
Chief, Clinical
Neuropharmacology Branch
National Institute
of Mental Health
Bethesda, Maryland

Ghanshyam N. Pandey, Ph.D.
Illinois State
Psychiatric Institute
Chicago, Illinois

Robert F. Prien, Ph.D.
Psychopharmacology
Research Branch
National Institute
of Mental Health
Rockville, Maryland

Ole J. Rafaelsen, M.D.
Professor of
Biological Psychiatry
Psychochemistry Institute
University of Copenhagen
Copenhagen, Denmark

Arthur Rifkin, M.D.
New York State
Psychiatric Institute
New York, New York

Janusz Rybakowski, M.D.
Department of Psychiatry
Academy of Medicine
Poznan, Poland

Mogens Schou, M.D.
Professor of
Biological Psychiatry
Aarhus University
Risskov, Denmark

Michael H. Sheard, M.D.
Professor of Psychiatry
Yale University
School of Medicine
New Haven, Connecticut

Baron Shopsin, M.D.
Associate Professor of
Psychiatry
New York University
School of Medicine
New York, New York

Irwin Singer, M.D.
Associate Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Donald F. Smith, Ph.D.
Psychopharmacology
Research Unit
Aarhus University
Risskov, Denmark

Thomas H. Steele, M.D.
Department of Medicine
University of Wisconsin
Madison, Wisconsin

K. Thomsen, dr. med.
Psychopharmacology
Research Unit
Aarhus University
Risskov, Denmark

Daniel C. Tosteson, M.D.
Dean
Harvard Medical School
Boston, Massachusetts

Joe P. Tupin, M.D.
Professor and Chairman
Department of Psychiatry
University of California–Davis
Davis, California

Stephen P. Tyrer, M.D.
Visiting Associate
Professor of Psychiatry
Queen's University
Kingston, Ontario, Canada

Daniel P. van Kammen, M.D.
Chief, Clinical
Research Unit
Biological Psychiatry
Branch
National Institute
of Mental Health
Bethesda, Maryland

Morton R. Weinstein, M.D.
Professor of Psychiatry
University of California –
San Francisco
School of Medicine
San Francisco, California

Jan Wolff, M.D.
National Institute of
Arthritis and Metabolic
Diseases
National Institutes of Health
Bethesda, Maryland

Petr Zvolisky, MUDr., C.Sc.
Research Psychiatry Unit
Charles University
Prague, Czechoslovakia

INTRODUCTION

Nathan S. Kline

Director of Research, Rockland Research Institute,
Orangeburg, New York, and Clinical Professor, Department of
Psychiatry, College of Physicians and Surgeons, Columbia
University, New York, U.S.A.

In the summer of 1978, almost 30 years after lithium was first introduced into psychiatric treatment, a large scale international meeting was held to review the subject in depth. The full five days had to be scheduled to include both the relevant topics and the 60 relevant investigators. Concern was expressed that a five-day meeting held in the center of New York City would be subject to seepage and erosion since the customary time was two and one-half days. The organizers were adamant in their insistence that a shorter time would be unacceptable.

The participants were invited with the clear understanding that they would be present for the entire five days. The exceptions granted were to the nephrologists for whom most of the sessions were not relevant and to Dr. Tosteson who, as Dean of the Harvard Medical School, was permitted to go back to Boston for graduation ceremonies. With very few other exceptions, all the participants were present for all the sessions.

The meeting was closed not only to the general public but to the medical and psychiatric "public" as well. The purpose of this was to keep the group small and intimate enough to encourage as much communication as possible between those having expertise in different aspects of the problem. No publicity was given to the meeting and reporters from two medical publications who heard about the event were firmly but politely refused admission. Among other reasons for so doing was that we felt reporters might inhibit the discussions. One of them was quite indignant and threatened to "take action" because a few of the participants from the National Institute of Mental Health were "being paid with his tax dollars."

The present volume more than adequately justifies the time and effort of the participants. Incidentally, all of the discussion was recorded. We have reviewed it and included those parts which are not covered in the formal papers.

Those who worked with lithium -- and, for that matter, other psychopharmaceuticals -- some quarter of a century ago were quite hardy and independent-minded investigators and clinicians. They were tough enough to

buck the psychodynamic tide which in some countries threatened to inundate psychiatry. Their fortitude and resilience is evidenced by their ability to change psychiatry -- and by their high survival rate.

Gershon, Kline and Schou were responsible for the selection of the participants. Heinz Lehmann served as general consultant. Tom Cooper competently carried the heavy burden of secretary and general director. In addition to reporting our own research (lithium in the management of alcoholism), I served as overall organizer and "producer." Excerpta Medica arranged the practical aspects of the meeting which, in turn, was underwritten by SmithKline Corporation. The meeting was officially sponsored by the National Institute of Mental Health, New York University College of Medicine and the Rockland Research Institute of the New York State Office of Mental Health.

Most of us respond up to the level of our audience. And here was an audience of most of the world's best informed psychopharmacologists and clinicians in the area of lithium research. They dealt not only with the conventional and accepted, but with the unresolved issues and controversies. Because the group was knowledgeable, critical and curious, the presentations were unusually concise, clearly stated and often provocative. The free-ranging discussions led at times to a clash of opinion and information. Some problems that might have dragged on in the literature for years were resolved. Insights sparked by the unfamiliar and original led to the recognition of new and more relevant questions to be answered.

CONTENTS

I. PSYCHIATRIC USES – I

Chairman – Robert F. Prien, Ph.D.

Clinical uses of lithium – Part I: Introduction	
<i>R. F. Prien</i>	3
The use of lithium in child and adolescent psychiatry	
<i>B. Lena</i>	30
Lithium as an antidepressant	
<i>J. Mendels, T. A. Ramsey, W. L. Dyson and A. Frazer</i>	35
The role of lithium in the prophylaxis of affective disorders, in psychosomatic conditions, and in several nonpsychiatric disorders	
<i>A. Rifkin</i>	48
Lithium in manic-depressive illness: some highlights and current controversies	
<i>A. Georgotas and S. Gershon</i>	57
Lithium treatment in schizophrenia: a review of treatment and prophylaxis in schizophrenia, schizoaffective disorders, and periodic catatonia	
<i>D. P. Van Kammen and E. G. De Fraites</i>	85
Lithium, a potential treatment of drug abuse? A review	
<i>D. P. Van Kammen</i>	98

II. PSYCHIATRIC USES – II

Chairman – Professor Mogens Schou

Psychiatric uses II	
<i>M. Schou</i>	109
Alcoholism: introduction	
<i>M. Schou</i>	120
Lithium in the treatment of chronic alcoholism	
<i>N. S. Kline, T. B. Cooper, J. A. Bennett, A. Calobrisi, T. H. Neidengard and A. F. Snyder</i>	122
Two-year follow-up of alcoholic patients formerly treated with lithium/placebo	
<i>J. Merry and A. Coppen</i>	129
Pathologic impulsive aggressiveness: introduction	
<i>M. Schou</i>	135
Lithium and aggressive behavior	
<i>M. H. Sheard and J. L. Marini</i>	136
Some points concerning the clinical evidence for an antiaggressive effect of lithium	
<i>P. Zvolský and T. Dostál</i>	149
Clinical use of lithium salts from the genetic viewpoint	
<i>P. Zvolský, M. Dvořáková, K. Souček, E. Vinařová and T. Dostál</i>	152

III. NONPSYCHIATRIC USES

Chairmen – Robert F. Prien, Ph.D., Professor Mogens Schou

Nonpsychiatric uses

R. F. Prien and M. Schou

157

IV. PREDICTION OF TREATMENT OUTCOME

Chairman – Bernard J. Carroll, M.D., Ph.D.

Prediction of treatment outcome with lithium

B. J. Carroll

171

Erythrocyte concentrations of the lithium ion

*A. Frazer, J. Mendels, T. A. Ramsey, D. Brunswick, J. London,
M. Pring and J. Rybakowski*

198

On the relevance of the red blood cell/plasma lithium ratio

W. Greil, B. F. Becker and J. Duhm

209

Red blood cell/lithium ratio in patients with affective disorders

J. Rybakowski

218

Prediction of treatment outcome: family and twin studies in lithium prophylaxis and the question of lithium red blood cell/plasma ratios

J. Medlewicz

226

Biological and clinical predictions of lithium response in depression

*J. I. Nurnberger, E. S. Gershon, D. L. Murphy, M. S. Buchsbaum,
F. K. Goodwin, R. M. Post, C. R. Lake, J. J. Guroff and
M. H. McGinnis*

241

Lithium-pump repression as an indicator of prophylactic response

R. R. Fieve, H. L. Meltzer, D. L. Dunner and J. L. Fleiss

257

V. TREATMENT MANAGEMENT – I

Chairman – Paul Grof, M.D.

Lithium treatment and management: introduction

P. Grof

265

Lithium in mania: comparisons with neuroleptics and the issue of specificity

F. K. Goodwin and A. P. Zis

282

The standardized twelve-hour serum or plasma concentration (12h-stSLi) in lithium therapy and the use of lithium concentration in lithium intoxication. The vital necessity of continuous self-supervision

A. Armdisen

304

Minimum effective plasma lithium levels for long-term preventive treatment of recurrent affective disorders

R. P. Hullin

333

Bioavailability of lithium preparations: differences unrelated to manufacturers' designation

S. P. Tyrer

335

Sustained-release preparations of lithium carbonate

R. P. Hullin

341

Issues related to the prediction of optimum dosage <i>T. B. Cooper and G. M. Simpson</i>	346
Selection of affectively ill patients for long-term treatment: introduction <i>P. Grof</i>	354
Selection of patients with recurrent affective illness for a long-term study: testing research criteria on prospective follow-up data <i>J. Angst and P. Grof</i>	355
Selection of an individual patient for long-term lithium treatment in clinical practice <i>P. Grof, J. Angst, M. Karasek and G. Keitner</i>	370
The natural course of affective disorders: implications for lithium prophylaxis <i>A. P. Zis, P. Grof and F. K. Goodwin</i>	381

VI. TREATMENT MANAGEMENT – II

Chairman – A. Coppen, M.D.

Lithium prophylactic therapy in unipolar depression and some possible prognosticators of response <i>A. Coppen, M. Metcalfe and J. Bailey</i>	401
Absolute and relative contraindications for prophylactic lithium treatment <i>P. C. Baastrup</i>	413
Pharmacokinetics of lithium: predicting optimal dosage <i>S. S. Chang, G. N. Pandey, R. C. Casper, C. O. Kinard and J. M. Davis</i>	419
Complications of lithium treatment in older patients <i>D. L. Dunner, S. P. Roose and S. Bone</i>	427
Lithium teratogenesis: the register of lithium babies <i>M. R. Weinstein</i>	432

VII. SIDE EFFECTS

Chairman – Samuel Gershon, M.D.

Toxicology and side effects of lithium therapy <i>B. Reisberg and S. Gershon</i>	449
The effect of lithium on normal mood, cognition and personality function <i>L. L. Judd</i>	479
Effects of lithium on vigilance, performance, memory and mood of healthy volunteers <i>B. Müller-Oerlinghausen, D. Kropf, W. M. Herrmann and S. Hamann</i>	497
Sudden death during lithium carbonate maintenance <i>B. Shopsin, H. Temple, M. Ingwer, S. Kane and J. Hirsch</i>	527
Lithium interactions with the thyroid gland <i>J. Wolff</i>	552

VIII. LITHIUM AND THE KIDNEY/LITHIUM POISONING

Chairman – F. A. Jenner, M.D.

Lithium and the kidney	
<i>F. A. Jenner</i>	567
Kidney function and morphology in long-term lithium treatment	
<i>O. J. Rafaelsen, T. G. Bolwig, J. Ladefoged and C. Brun</i>	578
Effects on renal and thyroid function and bone metabolism in long-term maintenance treatment with lithium salts	
<i>R. P. Hullin and N. J. Birch</i>	584
Toxic effects of lithium on the kidney	
<i>K. Thomsen</i>	619
Lithium-induced polyuria: cellular mechanisms and response to diuretics	
<i>J. N. Forrest</i>	632
Lithium-induced renal tubular acidosis	
<i>I. Singer and M. Cox</i>	642
Lithium-induced natriuresis	
<i>M. Cox and I. Singer</i>	646
Effects of lithium in the isolated perfused rat kidney	
<i>T. H. Steele, B. A. Stromberg and J. L. Underwood</i>	656

IX. MODE OF ACTION

Chairmen – W. E. Bunney Jr., M.D., A. J. Mandell, M.D.

Mechanisms of action of lithium: introduction	
<i>W. E. Bunney Jr. and A. J. Mandell</i>	673
Some biological considerations of the mode of action of lithium in the treatment of affective illness	
<i>W. E. Bunney Jr., A. Pert, J. Rosenblatt and C. B. Pert</i>	675
Effects of lithium on somatosensory evoked potentials and prediction of clinical response in patients with affective illness	
<i>M. S. Buchsbaum, R. A. Lavine, G. C. Davis, F. K. Goodwin, D. L. Murphy and R. M. Post</i>	685
Lithium and brain adenylate cyclase	
<i>R. P. Ebstein and R. H. Belmaker</i>	703
Lithium and catecholamine-induced plasma cyclic AMP elevation	
<i>E. Friedman, M. A. Oleshansky, P. Moy and S. Gershon</i>	730
Lithium transport in human red cells: genetic and clinical aspects	
<i>G. N. Pandey, E. Dorus, J. M. Davis and D. C. Tosteson</i>	736
The red cell membrane as a model for studying lithium's therapeutic action	
<i>B. E. Ehrlich, J. M. Diamond, C. Clausen, L. Gosenfeld and S. Kaufman-Diamond</i>	758
The effects of lithium on cell membranes	
<i>A. I. M. Glen</i>	768
Does lithium act by selectivity affecting a brain enkephalin system?	
<i>J. C. Gillin, J. S. Hong, H.-Y. T. Yang and E. Costa</i>	781

Asymmetry and mood, emergent properties of serotonin regulation: a mechanism of action of lithium	
<i>A. J. Mandell and S. Knapp</i>	789
Some new approaches to lithium's cellular and metabolic actions of potential relevance to its behavioral effects	
<i>D. L. Murphy and J. L. Costa</i>	815
The effects of lithium on amine transport and monoamine oxidase activity in brain	
<i>J. M. Davis, R. Colburn, D. Murphy and D. S. Robinson</i>	834
Delayed effects of lithium on the somatosensory evoked response and the acoustic startle reflex in cats and monkeys	
<i>G. R. Heninger and M. Davis</i>	841
Lithium as a regulator of prostaglandin synthesis	
<i>D. F. Horrobin</i>	854
Effects of lithium on thymus gland mediated functions in man and rodents	
<i>J. Perez-Cruet, J. Waite, A. Mallya and A. M. Khajawall</i>	881
Psychological approaches to lithium therapy	
<i>F. N. Johnson</i>	895
Six questions about lithium's effects on animal behaviour	
<i>D. F. Smith</i>	936
Animal behavior studies involving lithium	
<i>F. N. Johnson</i>	945
Lithium and the conditioned avoidance response	
<i>A. Judd</i>	952
The lithium information center	
<i>J. W. Jefferson, J. H. Greist and J. R. Marcetich</i>	958

X. LABORATORY METHODS

Chairman – Bernard J. Carroll, M.D., Ph.D.

Laboratory methods for measuring lithium transport	
<i>B. J. Carroll</i>	967
A procedure for the determination of Li^+ ratio in vitro of human erythrocytes	
<i>G. N. Pandey and J. M. Davis</i>	969
Determination of the Li ratio of human erythrocytes in vivo	
<i>A. Frazer</i>	976
Determination of the sodium-lithium countertransport system of human erythrocytes	
<i>M. L. Canessa and D. C. Tosteson</i>	978

Index of authors	983
-------------------------	-----

PSYCHIATRIC USES – I

Chairman – Robert F. Prien, Ph.D.

CLINICAL USES OF LITHIUM - PART I: INTRODUCTION

Robert F. Prien

Psychopharmacology, Research Branch, National Institute of Mental Health, Bethesda, Maryland, U.S.A.

This session will critically evaluate the clinical use of lithium in primary affective disorders, schizophrenia, and schizoaffective illness; mood and behavior disorders in children and adolescents; drug abuse; and psychosomatic disorders. The following session will focus on the use of lithium in other psychiatric disorders.

This paper will present an overview of the session topics. The topics will be discussed in more detail by the panelists Dr. Gershon, Dr. Lena, Dr. Mendels, Dr. Rifkin, and Dr. vanKammen.

USE IN PRIMARY AFFECTIVE DISORDERS

Long-Term Maintenance Therapy

It is appropriate to initiate the session on clinical use of lithium with a discussion of the effectiveness of long-term maintenance therapy with lithium for recurrent affective illness. The use of lithium maintenance treatment to prevent or attenuate recurrences of mania and depression has been described as one of the most important advances in psychiatric therapeutics (1). It has also been one of the most controversial. The "prophylactic" use of lithium had its origin in the late 1950s and early 1960s when several investigators reported that maintenance doses of lithium were effective in preventing recurrence of both depressive and manic episodes in patients with a history of frequent attacks (2-5). However, it was not until 1967 that long-term maintenance treatment with lithium attracted widespread attention. Baastrup and Schou conducted a large scale study comparing course of illness before lithium therapy against course of illness during lithium therapy and concluded that "lithium is the first drug demonstrated as a clear-cut prophylactic agent against one of the major psychoses" (6). This report prompted well-publicized rebuttals (7,8) and generated questions and controversies that have not been completely resolved.

Two diagnostic classifications have assumed prominent roles in the evaluation of long-term maintenance lithium treatment. These are the primary versus secondary classification and bipolar versus unipolar classification. Most of the studies on maintenance lithium

therapy are limited to patients with primary affective illness. As described by Robins and Guze (9), a primary affective illness is an affective disorder occurring in a patient who has no preexisting nonaffective psychiatric illness. Secondary affective illness is defined as a disorder occurring in a patient who has a preexisting psychiatric illness other than depression or mania.

The majority of maintenance lithium trials are analyzed in terms of the bipolar-unipolar dichotomy. This classification separates depressed patients with a history of mania (bipolar) from those with a history of only recurrent depression (unipolar). Occasionally, patients with recurrent mania and no history of depression are characterized as unipolar manic (10), although this usage is rarely employed in lithium studies. The bipolar classification has been further refined to include a second group, labeled bipolar II, consisting of patients who have a history of hypomanic episodes and depression but no history of mania.

The literature on long-term maintenance lithium therapy has been independently reviewed by two important committees in the United States - the Neuropsychopharmacology Advisory Committee to the Food and Drug Administration (FDA) and the American Psychiatric Association (APA) Task Force on Lithium Therapy. Both concluded that lithium has demonstrated superior efficacy over placebo in the treatment of bipolar recurrent affective illness. The FDA Advisory Committee's conclusion was made part of the revised Lithium Carbonate Package Insert (11), issued in 1974, which approved the use of lithium for the long-term maintenance treatment of bipolar affective illness. The insert states that maintenance therapy with lithium carbonate "prevents or diminished the intensity of subsequent episodes in those manic-depressive patients with a history of mania" (i.e., bipolar patients). The APA Task Force Report on Lithium Therapy (12), published in 1975, concurs with the FDA's position that lithium is effective in preventing or attenuating recurrences in bipolar illness.

There is no provision in the package insert for the long-term maintenance treatment of unipolar affective illness. Both the FDA Advisory Committee and the APA Task Force concluded that, although there is evidence that lithium is effective in unipolar recurrent affective illness, there is need for further evaluation of the drug's use in this disorder. In 1976, the FDA Advisory Committee reexamined the issue of lithium's effectiveness in unipolar illness and concluded that there was still insufficient evidence to warrant change in the approved indications for lithium therapy (13).

The FDA Advisory Committee and APA Task Force cited two reasons for failing to recommend use of lithium for the long-term maintenance treatment of unipolar illness. First, evidence for lithium's effectiveness in the dis-